Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 6 47-6, 2003, Pages

  Egan, Josephine M ^a   Meneilly, Graydon S ^b   Elahi, Dariush ^c,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

C peptide; Glucagon; Glucose disposal; Hemoglobin A1C; Insulinotropic effect

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HORMONE RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SELF ADMINISTRATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN SENSITIVITY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0038178058     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00315.2002     Document Type: Article

References (29)

1. Aspelund G, Egan J, Slezak L, Sritharan K, Elahi D, and Andersen D. Glucagon-like peptide-1 and exendin-4 improve glucose tolerance and induce islet cell growth during chronic pancreatitis in rats. Surgical Forums: L1, 2000.
2. Drucker D. Glucagon-like peptides. Diabetes 47: 159-169, 1998.
3. Drucker D. Minireview: the glucagon-like peptides. Endocrinology 142: 521-527, 2001.
4. Edwards C, Stanley S, Davis R, Brynes A, Frost G, Seal L, Ghatei M, and Bloom S. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281: E155-E161, 2001.
5. Egan J, Clocquet A, and Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87: 1282-1290, 2002.
6. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, and Andersen DK. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51: 63-74, 1994.
7. Flint A, Raben A, Astrup A, and Holst J. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520, 1998.
8. Greig N, Holloway H, De Ore K, Jani D, Wang Y, Zhou J, Garant M, and Egan J. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42: 45-50, 1999.
9. Gutzwiller J, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, and Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol Regul Integr Comp Physiol 276: R1541-R1544, 1999.
10. Hother-Nielsen O and Beck-Nielsen H. On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion. Diabetologia 33: 603-610, 1990.
11. Insel PA, Liljenquist JE, Tobin JD, Sherwin RS, Watkins P, Andres R, and Berman M. Insulin control of glucose metabolism in man: a new kinetic analysis. J Clin Invest 55: 1057-1066, 1975.
12. Kieffer TJ, McIntosh CH, and Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596, 1995.
13. Kolterman O, Fineman M, Gottlied A, Petrella E, Pricket K, and Young A. AC2993 (synthetic exendin-4) lowered postprandial plasma glucose concentrations in people with type 2 diabetes (Abstract). Diabetolgia Suppl 42: A149, 1999.
14. Montrose-Rafizadeh C, Yang H, Rodgers B, Beday A, Pritchette L, and Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 272: 21201-21206, 1997.
15. Nauck M, Kleine N, Orskov C, Holst J, Willms B, and Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 36: 741-744, 1993.
16. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, and Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
17. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, and Young A. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 53: 260-267, 2001.
18. Parkes D, Pittner R, Jodka C, Smith P, and Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50: 583-589, 2001.
19. Ryan A, Muller D, and Elahi D. Sequential hyperglycemiceuglycemic clamp to assess β-cell and peripheral tissue: studies in female athletes. J Appl Physiol 91: 872-881, 2001.
20. Ryan AS, Egan JM, Habener JF, and Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83: 2399-2409, 1998.
21. Somogi M. Determination of blood sugar. J Biol Chem 10: 69-73, 1945.
22. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82: 420-430, 1959.
23. Stoffers D, Kieffer T, Hussain M, Drucker D, Bonner-Weir S, Habener J, and Egan J. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49: 741-748, 2000.
24. Szayna M, Doyle M, Betkey J, Holloway H, Spencer R, Greig N, and Egan J. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141: 1936-1941, 2000.
25. Toft-Nielsen M, Madsbad S, and Holst J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetes patients. Diabetes Care 22: 1137-1143, 1999.
26. Verdich C, Flint A, Gutzwiller J, Naslund E, Beglinger C, Hellstrom P, Long S, Morgan L, Holst J, and Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86: 4382-4389, 2001.
27. Xu G, Stoffers D, Habener J, and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276, 1999.
28. Young A, Gedulin B, Bhavsar S, Bodkin N, Jodka C, Hansen B, and Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48: 1026-1034, 1999.
29. Zander M, Madsbad S, Madsen J, and Holst J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830, 2002.